Synchronous Deep Venous Thrombosis and Pulmonary Embolism in Stomach Cancer Patient: Case Report
Year 2019,
Volume: 6 Issue: 3, 156 - 159, 31.12.2019
Kağan Gökçe
,
Cihan Aydın
Emrah Doğan
,
Serkan Yazman
Abstract
Venous
thromboembolism (VTE) consists of deep vein thrombosis (DVT) and pulmonary
embolism (PE). The annual incidence of VTE in the general population is 117 per
100000. VTE is an important cause of morbidity and mortality. The incidence of
cancer-associated VTE is higher and the results are more dramatic. Stomach cancer
is the sixth most common type of cancer that causes death. The most common
histological subtype of stomach cancer is adenocarcinoma. Stomach cancer is the
third type of cancer that has the highest risk of cancer related
thromboembolism after pancreatic and lung cancer. The main treatment in cancer
related VTE is low molecular weight heparin (LMWH). The aim of this case report
is to present a 76 years old male patient with stomach cancer, synchronous
venous thrombosis and pulmonary embolism, who underwent surgery under LMWH
treatment.
References
- 1. Wu C, Lee AY. Novel or Non–Vitamin K Antagonist Oral Anticoagulants and the Treatment of Cancer-Associated Thrombosis Semin Thromb Hemost. 2015;41(2):237–43.
- 2. Walker AJ, Card TR, West J, Crooks C, Grainge MJ.Incidence of venous thromboembolism in patients with cancer-a cohort study using linked United Kingdom databases. Eur J Cancer 2013;49(6):1404–13.
- 3. Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies–systematic review and meta-analysis. Acta Oncologica. 2014;53(9):1230–7.
- 4. Farge D, Bounameaux H, Brenner B, et al. Implementing Thrombosis Guidelines in Cancer Patients: A Review. Rambam Maimonides Med J. 2014;5(4):0041.
- 5. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(1):132–75.
- 6. Wada T, Fujiwara H, Morita S, Fukagawa T, Katai H.Incidence of and risk factors for preoperative deep venous thrombosis in patients undergoing gastric cancer surgery. Gastric Cancer 2017;20(5):872–7.
- 7. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 1995;346(8981):1004–5.
- 8. Rickles FR, Brenner B. Tissue factor and cancer. Semin Thromb Hemost. 2008;34(2):143–5.
- 9. Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Rev. 2001;15(2):61–7.
- 10. Khorana AA, Liebman HA, White RH, et al. The Risk of Venous Thromboembolism in Patients with Cancer. American Society of Clinical Oncology; ASCO Educational Book; 2008;240–8.
- 11. Marshall-Webb M, Bright T, Price T, et al. Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy. Dis Esophagus. 2017;30(2):1–7.
- 12. Elyamany G, Alzahrani A.M, Bukhary E. Cancer-Associated Thrombosis: An Overview. Clin Med Insights Oncol. 2014;8:129-37.
- 13. Martin MJ, Blair KS, Curry TK, Singh N. Vena cava filters: current concepts and controversies for the surgeon. Curr Probl Surg. 2010;47(7):524–618.
- 14. Rojas-Hernandez CM, Zapata-Copete JA, García-Perdomo HA. Role of vena cava filters for the management of cancer-related venous thromboembolism: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;130:44–50.
Senkron Derin Ven Trombozu ve Pulmoner Embolisi Olan Mide Kanserli Hasta: Olgu Sunumu
Year 2019,
Volume: 6 Issue: 3, 156 - 159, 31.12.2019
Kağan Gökçe
,
Cihan Aydın
Emrah Doğan
,
Serkan Yazman
Abstract
Venöz tromboemboli (VTE), derin ven trombozu
(DVT) ve pulmoner emboli (PE)’den oluşur. VTE’nin genel popülasyonda yıllık
görülme oranı her 100.000’de 117’dir. VTE önemli bir morbidite ve mortalite
kaynağıdır. Kanserle ilişkili gelişen VTE’nin görülme insidansı daha fazladır
ve sonuçları daha dramatiktir. Mide kanseri en sık görülen ve ölüme yol açan
altıncı kanser tipidir. Mide kanserinin en sık görülen histolojik subtipi
adenokarsinomdur. Mide kanseri, pankreas ve akciğer kanserinden sonra kansere
bağlı tromboemboli riski en yüksek olan üçüncü kanser tipidir. Kansere bağlı
gelişen VTE’de esas tedavi düşük molekül ağırlıklı heparindir (DMAH). Bu vaka
takdiminin amacı; DMAH tedavisi altında ameliyat edilen, 76 yaşında, senkron
venöz trombozu ve pulmoner embolisi olan mide kanserli erkek hastayı sunmaktır.
References
- 1. Wu C, Lee AY. Novel or Non–Vitamin K Antagonist Oral Anticoagulants and the Treatment of Cancer-Associated Thrombosis Semin Thromb Hemost. 2015;41(2):237–43.
- 2. Walker AJ, Card TR, West J, Crooks C, Grainge MJ.Incidence of venous thromboembolism in patients with cancer-a cohort study using linked United Kingdom databases. Eur J Cancer 2013;49(6):1404–13.
- 3. Ben-Aharon I, Stemmer SM, Leibovici L, Shpilberg O, Sulkes A, Gafter-Gvili A. Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies–systematic review and meta-analysis. Acta Oncologica. 2014;53(9):1230–7.
- 4. Farge D, Bounameaux H, Brenner B, et al. Implementing Thrombosis Guidelines in Cancer Patients: A Review. Rambam Maimonides Med J. 2014;5(4):0041.
- 5. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(1):132–75.
- 6. Wada T, Fujiwara H, Morita S, Fukagawa T, Katai H.Incidence of and risk factors for preoperative deep venous thrombosis in patients undergoing gastric cancer surgery. Gastric Cancer 2017;20(5):872–7.
- 7. Kakkar AK, DeRuvo N, Chinswangwatanakul V, Tebbutt S, Williamson RC. Extrinsic-pathway activation in cancer with high factor VIIa and tissue factor. Lancet. 1995;346(8981):1004–5.
- 8. Rickles FR, Brenner B. Tissue factor and cancer. Semin Thromb Hemost. 2008;34(2):143–5.
- 9. Hoffman R, Haim N, Brenner B. Cancer and thrombosis revisited. Blood Rev. 2001;15(2):61–7.
- 10. Khorana AA, Liebman HA, White RH, et al. The Risk of Venous Thromboembolism in Patients with Cancer. American Society of Clinical Oncology; ASCO Educational Book; 2008;240–8.
- 11. Marshall-Webb M, Bright T, Price T, et al. Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy. Dis Esophagus. 2017;30(2):1–7.
- 12. Elyamany G, Alzahrani A.M, Bukhary E. Cancer-Associated Thrombosis: An Overview. Clin Med Insights Oncol. 2014;8:129-37.
- 13. Martin MJ, Blair KS, Curry TK, Singh N. Vena cava filters: current concepts and controversies for the surgeon. Curr Probl Surg. 2010;47(7):524–618.
- 14. Rojas-Hernandez CM, Zapata-Copete JA, García-Perdomo HA. Role of vena cava filters for the management of cancer-related venous thromboembolism: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2018;130:44–50.